Related Experiment Video
Updated: Aug 24, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
Low molecular weight heparins as thromboprophylaxis in patients undergoing hemodialysis/hemofiltration or continuous
Solbjørg Sagedal1, Anders Hartmann
1Department of Medicine, Rikshospitalet University Hospital, N-0027 Oslo, Norway. solbjorg.sagedal@rikshospitalet.no
Low molecular weight heparins (LMWHs) have potential advantages over unfractionated heparin (UFH). They interact less with platelets and may induce less bleeding. The risk for heparin induced thrombocytopenia is less, and the effect on serum lipids is favourable. The half-life is longer, allowing for one single bolus dose at start of hemodialysis (HD). In addition, LMWH is found to result in lower plasma potassium in HD patients compared to UFH. LMWHs have an established role in HD and hemofiltration (HF), but the reports on their efficacy and safety during continuous renal replacement therapy (CRRT) are scarce.
Low molecular weight heparins (LMWHs) have potential advantages over unfractionated heparin (UFH). They interact less with platelets and may induce less bleeding. The risk for heparin induced thrombocytopenia is less, and the effect on serum lipids is favourable. The half-life is longer, allowing for one single bolus dose at start of hemodialysis (HD). In addition, LMWH is found to result in lower plasma potassium in HD patients compared to UFH. LMWHs have an established role in HD and hemofiltration (HF), but the reports on their efficacy and safety during continuous renal replacement therapy (CRRT) are scarce.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemodialysis II: Procedure and Complications
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Venous Thrombosis III: Interprofessional Care
Continuous Renal Replacement Therapy
Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration